Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more
Medy-Tox Inc (086900) - Net Assets
Latest net assets as of September 2025: ₩467.65 Billion KRW
Based on the latest financial reports, Medy-Tox Inc (086900) has net assets worth ₩467.65 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩586.91 Billion) and total liabilities (₩119.26 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩467.65 Billion |
| % of Total Assets | 79.68% |
| Annual Growth Rate | 20.47% |
| 5-Year Change | 95.02% |
| 10-Year Change | 314.85% |
| Growth Volatility | 20.52 |
Medy-Tox Inc - Net Assets Trend (2013–2024)
This chart illustrates how Medy-Tox Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medy-Tox Inc (2013–2024)
The table below shows the annual net assets of Medy-Tox Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩470.78 Billion | -0.78% |
| 2023-12-31 | ₩474.48 Billion | +10.85% |
| 2022-12-31 | ₩428.04 Billion | +7.15% |
| 2021-12-31 | ₩399.48 Billion | +65.49% |
| 2020-12-31 | ₩241.40 Billion | -6.85% |
| 2019-12-31 | ₩259.15 Billion | +2.60% |
| 2018-12-31 | ₩252.59 Billion | +31.79% |
| 2017-12-31 | ₩191.65 Billion | +29.78% |
| 2016-12-31 | ₩147.68 Billion | +30.13% |
| 2015-12-31 | ₩113.48 Billion | +39.09% |
| 2014-12-31 | ₩81.59 Billion | +34.45% |
| 2013-12-31 | ₩60.68 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medy-Tox Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42521059200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩425.21 Billion | 91.15% |
| Common Stock | ₩3.65 Billion | 0.78% |
| Other Components | ₩37.62 Billion | 8.06% |
| Total Equity | ₩466.48 Billion | 100.00% |
Medy-Tox Inc Competitors by Market Cap
The table below lists competitors of Medy-Tox Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
$411.88 Million |
|
iHeartMedia Inc Class A
NASDAQ:IHRT
|
$411.91 Million |
|
Scales Corporation Limited
F:S05
|
$411.92 Million |
|
Qualipoly Chemical Corp
TW:4722
|
$412.26 Million |
|
Mangalore Refinery and Petrochemicals Limited
NSE:MRPL
|
$411.84 Million |
|
Vinati Organics Limited
NSE:VINATIORGA
|
$411.77 Million |
|
SPAREBKN MORE NK 20
F:K5X
|
$411.70 Million |
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
$411.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medy-Tox Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 469,462,692,180 to 466,475,912,000, a change of -2,986,780,180 (-0.6%).
- Net income of 16,954,995,000 contributed positively to equity growth.
- Dividend payments of 8,424,486,000 reduced retained earnings.
- Share repurchases of 10,006,878,000 reduced equity.
- New share issuances of 141,200,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩16.95 Billion | +3.63% |
| Dividends Paid | ₩8.42 Billion | -1.81% |
| Share Repurchases | ₩10.01 Billion | -2.15% |
| Share Issuances | ₩141.20 Million | +0.03% |
| Other Changes | ₩-1.65 Billion | -0.35% |
| Total Change | ₩- | -0.64% |
Book Value vs Market Value Analysis
This analysis compares Medy-Tox Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.11x to 1.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩22598.45 | ₩115400.00 | x |
| 2017-12-31 | ₩31047.07 | ₩115400.00 | x |
| 2018-12-31 | ₩40859.62 | ₩115400.00 | x |
| 2019-12-31 | ₩42167.01 | ₩115400.00 | x |
| 2020-12-31 | ₩39531.64 | ₩115400.00 | x |
| 2021-12-31 | ₩65971.37 | ₩115400.00 | x |
| 2022-12-31 | ₩67544.36 | ₩115400.00 | x |
| 2023-12-31 | ₩69765.75 | ₩115400.00 | x |
| 2024-12-31 | ₩70047.44 | ₩115400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medy-Tox Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.42%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.32x
- Recent ROE (3.63%) is below the historical average (21.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 23.57% | 36.54% | 0.49x | 1.31x | ₩8.24 Billion |
| 2014 | 53.47% | 57.49% | 0.45x | 2.07x | ₩35.47 Billion |
| 2015 | 37.27% | 47.79% | 0.43x | 1.79x | ₩30.94 Billion |
| 2016 | 40.11% | 44.45% | 0.41x | 2.19x | ₩44.46 Billion |
| 2017 | 36.58% | 38.68% | 0.48x | 1.99x | ₩50.94 Billion |
| 2018 | 27.70% | 34.05% | 0.52x | 1.56x | ₩44.70 Billion |
| 2019 | 10.11% | 12.73% | 0.49x | 1.63x | ₩290.81 Million |
| 2020 | -12.25% | -21.00% | 0.30x | 1.94x | ₩-53.72 Billion |
| 2021 | 23.57% | 50.93% | 0.32x | 1.45x | ₩54.21 Billion |
| 2022 | 8.65% | 18.97% | 0.33x | 1.39x | ₩-5.79 Billion |
| 2023 | 2.08% | 4.41% | 0.36x | 1.30x | ₩-37.19 Billion |
| 2024 | 3.63% | 7.42% | 0.37x | 1.32x | ₩-29.69 Billion |
Industry Comparison
This section compares Medy-Tox Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medy-Tox Inc (086900) | ₩467.65 Billion | 23.57% | 0.26x | $411.84 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |